Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity
- PMID: 12224022
- DOI: 10.1038/sj.cgt.7700502
Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity
Abstract
Antitumor effects of combined transfer of P16 and cytokine genes were investigated in this study. The adenovirus harboring the P16 gene (AdP16) and murine granulocyte-macrophage colony-stimulating factor gene (AdGM-CSF) were utilized for the treatment of established tumors. The mice were inoculated subcutaneously with Renca cells and, 6 days later, received an intratumoral injection of AdP16 in the presence or absence of AdGM-CSF. The results demonstrated that tumor-bearing mice treated with AdP16 in combination with AdGM-CSF showed more potent inhibition of tumor growth and survived much longer than did mice treated with AdP16, AdGM-CSF, adenovirus expressing beta-galactosidase, or phosphate-buffered saline alone (P<.01). The tumor mass showed obvious necrosis and inflammatory cell infiltration, and more CD(4)(+) and CD(8)(+) T cells infiltrating the tumor after combined therapy. After combined therapy, the expression of MHC-1 (H-2K(d)) and Fas molecules on freshly isolated tumor cells increased greatly. The activity of specific cytotoxic T lymphocytes was also found to be induced more significantly after the combined therapy (P<.01). Our results demonstrated that combined therapy with P16 and GM-CSF genes can inhibit the growth of established tumors in mice significantly and induce antitumor immunity of the host efficiently.
Similar articles
-
Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte-macrophage colony-stimulating factor gene transfer.Cancer Gene Ther. 2000 Feb;7(2):177-86. doi: 10.1038/sj.cgt.7700114. Cancer Gene Ther. 2000. PMID: 10770625
-
Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice.Gene Ther. 1998 Aug;5(8):1130-6. doi: 10.1038/sj.gt.3300727. Gene Ther. 1998. PMID: 10326037
-
[Effects of p16 and GM-CSF combined gene therapy on immune response of tumor-bearing mice].Zhonghua Wai Ke Za Zhi. 2000 Dec;38(12):939-42. Zhonghua Wai Ke Za Zhi. 2000. PMID: 11832203 Chinese.
-
Cellular and molecular studies in the treatment of murine renal cancer.Semin Oncol. 1995 Feb;22(1):9-16. Semin Oncol. 1995. PMID: 7855624 Review.
-
Bioactivity of human GM-CSF gene therapy in metastatic renal cell carcinoma and prostate cancer.Hinyokika Kiyo. 1997 Nov;43(11):821-2. Hinyokika Kiyo. 1997. PMID: 9436029 Review. No abstract available.
Cited by
-
Construction and application of adenoviral vectors.Mol Ther Nucleic Acids. 2023 Sep 9;34:102027. doi: 10.1016/j.omtn.2023.09.004. eCollection 2023 Dec 12. Mol Ther Nucleic Acids. 2023. PMID: 37808925 Free PMC article. Review.
-
Lessons learned from next-generation sequencing in head and neck cancer.Head Neck. 2013 Mar;35(3):454-63. doi: 10.1002/hed.23100. Epub 2012 Aug 21. Head Neck. 2013. PMID: 22907887 Free PMC article. Review.
-
Granulocyte-macrophage colony-stimulating factor: not just another haematopoietic growth factor.Med Oncol. 2014 Jan;31(1):774. doi: 10.1007/s12032-013-0774-6. Epub 2013 Nov 22. Med Oncol. 2014. PMID: 24264600 Review.
-
The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response.NPJ Precis Oncol. 2021 Jun 22;5(1):56. doi: 10.1038/s41698-021-00200-4. NPJ Precis Oncol. 2021. PMID: 34158591 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous